证券代码：301029 证券简称：怡合达 东莞怡合达自动化股份有限公司 投资者关系活动记录表 编号：2025-007 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑ 现场参观 ☑ 其他（电话会议） 参与单位名称 详见附件《与会清单》 时间 2025 年 9 月 8 日-9 月 25 日 地点 线上：电话会议 线下：东莞市横沥镇村尾桃园二路 33 号、北京策略会、香港策略 会、上海策略会等 上市公司接待 人员姓名 董事会秘书：张美琪 投资者关系代表：范见涛 证券事务代表：廖芙雨、杨景凤 投资者关系活 动主要内容介 绍 本次调研活动主要问题及回答如下： Q1：介绍出海业务的出发点、难度与进程？ A："全球化"是怡合达始终坚守的核心战略信念。投身全球 化浪潮，便能发现我们在不少方面还有进步空间，通过全球化这 面镜子，看到自身不足的同时，更坚定了企业自我革新、自我超 越的决心。通过不断提升产品水平，不断精进，明确改进与发展 的方向，持续奋进，让产品能够高效触达并服务全球客户，稳步 提升怡合达在全球市场的影响力。由于公司业务具有产品线多、 SKU 多、终端用 ...

Core Viewpoint - The AI healthcare sector is in a nurturing phase, with increasing interest from public funds, particularly in overseas expansion as a key growth driver for companies in this field [1][2][6]. Group 1: Investment Trends - Public funds are heavily investing in AI healthcare companies, with a focus on those expanding internationally, such as JingTai Holdings and YiDu Technology, which are seeing significant revenue growth from overseas markets [2][3]. - Companies like Mirxes have reported that approximately 70% of their revenue comes from international markets, indicating a strong reliance on overseas expansion for growth [3]. Group 2: Valuation Concerns - Despite the growth potential, many AI healthcare companies are facing high valuations, with some trading at sales multiples of tens or even hundreds, raising concerns about sustainability [4][5]. - For instance, Mirxes has a market capitalization exceeding HKD 17 billion, which is notably higher than its competitors like Grail, despite Grail having significantly larger revenue [4]. Group 3: Future Outlook - Fund managers believe that the current high valuations are linked to the varying stages of commercialization among companies, with U.S. firms having a head start in the market [6][8]. - The AI healthcare sector is expected to see accelerated growth in the coming years, particularly in areas like brain-computer interfaces, which are projected to transition from laboratory to clinical applications within 1-2 years [8].

Core Viewpoint - Han's Information (300170) has established a strong partnership with Oracle, being recognized as an "Oracle Platinum Partner," which enhances its capabilities in international business [1] Group 1: Partnership and Collaboration - The company has developed a good ecological cooperation with Oracle, complementing each other's product and service capabilities [1] - Han's Information has served numerous outstanding international and Chinese enterprises over its 20+ years of development [1] Group 2: Global Expansion and Localization - The company actively collaborates with partners, including Oracle, to quickly respond to local financial, tax, invoicing, and e-government needs as enterprises establish production and manufacturing bases globally [1] - Han's Information aims to transform the Chinese ecosystem into a global ecosystem through its partnerships [1]

Core Insights - The report from CITIC Securities indicates that the overall A-share mid-year report in 2025 is still in a bottoming phase, with revenue growth and ROE stabilizing in the non-financial sector [1] Financial Performance - In Q2 2025, the net profit year-on-year growth rates for all A-shares, financial, and non-financial sectors were +1.5%, +5.8%, and -1.9% respectively, reflecting a low volatility characteristic [1] - The industrial sector's net profit is primarily dragged down by commodity prices, while consumer profit growth is declining [1] - The TMT sector shows the fastest year-on-year profit growth, aligning well with market trends [1] - The financial sector's incremental growth mainly comes from brokerage firms [1] International Business Impact - Despite facing challenges such as tariffs, exchange rate losses, and cash flow pressures, a number of representative companies have seen their overseas business significantly boost overall revenue and profit margins [1] - The expansion into international markets is identified as a key factor for exceeding expectations in the mid-year report [1]

Core Viewpoint - A-share companies are currently experiencing a bottoming out in profitability, with a notable structural divergence in performance across sectors [2][3] Summary by Sections Overall Performance - A-share companies' total revenue growth for the first half of the year is -0.02%, while non-financial enterprises show a decline of -0.53% year-on-year, indicating a slight improvement compared to the first quarter [2] - Net profit growth for A-share companies is 2.42%, and for non-financial enterprises, it is 0.98%, both showing a decline from the first quarter [2] - The second quarter's net profit growth for non-financial enterprises reached a seasonal low since 2010, primarily driven by financial companies [2] - Return on Equity (ROE) for A-share companies is 7.76%, and for non-financial enterprises, it is 6.55%, both down from the previous quarter [2] - Cash flow analysis shows that while net cash flow remains negative, operational, investment, and financing cash flows have improved, with non-financial real estate companies maintaining high free cash flow levels, indicating strong potential for dividends [2] Structural Performance - High-tech and overseas-oriented companies are performing well, while domestic consumption sectors are still recovering [3] - The net profit growth for the Sci-Tech Innovation Board exceeded 20% in the second quarter, leading the market, with significant contributions from the AI, semiconductor, and innovative pharmaceutical sectors [3] - Companies focused on overseas markets, as indicated by the Outbound 50 Index, reported a revenue growth of 12% and a 0.6% increase in ROE, outperforming the overall market [3] - Companies with over 10% of revenue from overseas markets are seeing a recovery in profit margins and ROE, making overseas business a key growth driver [3] - In contrast, domestic consumer goods sectors have shown a significant decline in growth rates compared to the first quarter, indicating a need for recovery in domestic consumption [3] - Overall, A-share companies' profitability is gradually solidifying, with innovation and overseas expansion becoming new growth points [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 21.39 [5][4]. Core Views - The company's revenue for H1 2025 reached RMB 1.701 billion, representing a year-over-year increase of 7.00%, while net profit attributable to shareholders was RMB 382 million, up 5.24% year-over-year [1][2]. - The company is expected to achieve growth through quality improvement and business optimization, despite stable waste incineration capacity [1]. - The expansion into intelligent computing centers, heating services, and overseas markets is anticipated to contribute positively to performance [1][3]. Revenue Breakdown - For H1 2025, the revenue from household waste disposal was RMB 1.252 billion (up 3.50% YoY) with a gross margin of 49.89% (up 1.85 percentage points YoY) [2]. - The revenue from kitchen waste disposal was RMB 211 million (up 6.69% YoY) with a gross margin of 36.07% (up 3.41 percentage points YoY) [2]. - The company reported losses in resource recycling businesses, including a loss of RMB 19.76 million from waste rubber recycling and a loss of RMB 20.23 million from waste battery recycling [2]. Business Expansion - The company has completed the registration of the "Zero Carbon Intelligent Computing Center" project with a processing capacity of 2,150 tons per day [3]. - The heating business has seen significant growth, with a total heating volume of 747,300 tons in H1 2025, an increase of over 24% year-over-year [3]. - A contract was signed with Vietnam's Thai Binh Province for a solid waste incineration plant project with a minimum daily processing capacity of 600 tons [3]. Financial Projections - The company is projected to achieve net profits of RMB 597 million, RMB 631 million, and RMB 678 million for the years 2025, 2026, and 2027, respectively [4][9]. - The target price of RMB 21.39 is based on a price-to-earnings (PE) ratio of 15.5 times for 2025, reflecting a positive outlook compared to the previous target price of RMB 17.80 [4][5].

Core Viewpoint - The custom home furnishing industry is still affected by the downturn in the real estate market, with companies waiting for recovery. Major players like Sophia, Shangpin, and Zhibang have reported revenue declines, while Gujia is one of the few companies experiencing growth. The industry is facing price wars that could harm its ecosystem [2][3][7]. Company Performance - Sophia's revenue for the first half of the year was 4.551 billion yuan, a decrease of 7.68% year-on-year, with a net profit of 319 million yuan, down 43.43% [3]. - Zhibang's revenue was 1.899 billion yuan, a decline of 14.14%, with a net profit of 138 million yuan, down 7.21% [5]. - Shangpin's revenue was 1.552 billion yuan, a decrease of 9.24%, and it reported a net loss of 80.67 million yuan [6]. - Gujia's revenue reached 9.801 billion yuan, an increase of 10.02%, with a net profit of 1.021 billion yuan, up 13.89% [6]. Market Trends - The industry is experiencing significant pressure, with overall revenue and profit declines being the main trend. The "old-for-new" home decoration policies have not sufficiently boosted company performance [3][5]. - Price wars are prevalent, with some companies offering prices below 1,000 yuan per square meter, which could lead to a decline in product quality [7]. - Companies are exploring overseas markets as a new growth point, with Sophia reporting a 39.49% increase in export revenue to 34.30 million yuan [3][4]. Future Outlook - The industry sees potential in home renovation and aging-friendly modifications as future growth areas. Companies believe that with continued policy support and improving market expectations, the custom home furnishing industry may stabilize and recover [8].

Group 1: Internet Industry Performance - In the first seven months, the revenue of large-scale internet enterprises in China exceeded 1.1 trillion yuan, reaching 11,352 billion yuan, with a year-on-year growth of 3.5%, an increase of 0.4 percentage points compared to the first half of the year [2] - The profit for the same period was 938.8 billion yuan, showing a year-on-year decline of 1.8%, but the decline rate narrowed significantly by 6.5 percentage points compared to the first half of the year [2] - The top five regions in terms of internet business revenue were Beijing, Guangdong, Shanghai, Zhejiang, and Guizhou, accounting for 84.6% of the national internet business revenue [2] Group 2: Logistics Industry Trends - The logistics industry prosperity index for August recorded 50.9%, an increase of 0.4 percentage points from the previous month, indicating a clear expansion [4] - The business volume index and new order index have both been in the expansion range for six and seven consecutive months, respectively [4] - The recovery in logistics demand is supported by high growth in high-end manufacturing and the release of consumer demand due to policy support [4][5] Group 3: Real Estate Market Dynamics - In August, Shanghai's second-hand housing transactions reached 19,912 units, a month-on-month increase of 2.76% and a year-on-year increase of 11.34%, marking the highest level for the same period since 2021 [6] - The new policies in Beijing and Shanghai have positively impacted the real estate market, contributing to a recovery in both new and second-hand housing markets [6][7] - The confidence of real estate companies in land acquisition has increased due to the sales recovery of quality projects in core urban areas [7] Group 4: New Energy Vehicle Market - New energy vehicle manufacturers such as Leap Motor, Xpeng Motors, and NIO achieved record high delivery volumes in August, with Leap Motor delivering 57,100 units, a year-on-year increase of 88% [10] - The overall growth rate of the new energy vehicle market is slowing, despite the strong performance of individual companies [11] Group 5: E-commerce Expansion - JD.com has made a voluntary public acquisition offer for CECONOMY, valuing the transaction at approximately 22 billion euros, equivalent to over 180 billion yuan [12] - JD.com's strategy focuses on local e-commerce expansion in overseas markets, contrasting with other platforms that rely on cross-border e-commerce [13] Group 6: A-share Market Financing - The total financing balance of A-shares reached a historical high of 2.28 trillion yuan, with the Shanghai Stock Exchange reporting a balance of 1.16 trillion yuan and the Shenzhen Stock Exchange reporting 1.11 trillion yuan [14] - The increase in financing balance is attributed to high daily trading volumes, with average daily trading around 2.5 trillion yuan [14][15]

Summary of MicroPort Medical's Conference Call Company Overview - **Company**: MicroPort Medical - **Period**: First half of 2025 - **Revenue**: Approximately $550 million, a year-on-year decrease of 2% after excluding currency effects, but a quarter-on-quarter increase of 16% in domestic market revenue [2][3][23] Key Financial Metrics - **Gross Margin**: 56.4%, higher than expected [2][23] - **Net Loss**: Reduced by 66% to $36 million [2][25] - **EBITDA**: Increased by 116% to $128 million [2][25] - **Operating Expenses**: Decreased by 14.5% year-on-year [2][23] - **R&D Expenses**: Significantly reduced by 37% [2][23] - **Cash Reserves**: Increased to $1.04 billion [2][27] Business Performance Highlights - **International Business Growth**: Revenue from overseas operations grew by 57.3%, with significant contributions from: - Cardiac intervention overseas revenue up 95% - Neuroscience overseas revenue up 67.4% - MicroPort Robotics overseas market growth nearly tripled [2][3][12] - **Cardiovascular Intervention**: Net profit increased by 64.4%, with a net profit margin of 21% [2][11] - **Orthopedic Business**: Net loss significantly narrowed by 58%, with EBITDA growth of 29% [2][11] - **Heart Valve Business**: Net loss reduced by 96.2%, with TAVI implant volume reaching 2,146 cases [2][21] Strategic Developments - **New Strategic Investor**: Introduction of state-owned Shanshi Capital as a strategic shareholder, expected to enhance business expansion and governance [2][8][39] - **Business Restructuring**: Strategic reorganization of heart rhythm and management businesses to create a unique global cardiac product platform [2][8] Challenges Faced - **Market Pressures**: Challenges include price pressure from domestic centralized procurement, cautious hospital selections due to anti-corruption measures, and delays in new product approvals [4][16] - **Geopolitical Impact**: The orthopedic business faced revenue shortfalls due to US-China tariffs and geopolitical conflicts affecting the supply chain [6][31] Future Outlook - **Revenue Guidance**: Adjusted to high single-digit growth for the year, with cardiovascular business expected to grow by 15% and heart rhythm management adjusted to 6% [5][28][29] - **Innovation and Market Expansion**: Continued focus on innovation, expanding market reach, and enhancing supply chain flexibility [12][45] - **Debt Management**: Plans to reduce debt levels from approximately 70% to around 50% over the next 1-3 years [53][50] R&D and Product Development - **Clinical Trials**: Successful clinical trials for the Firehawk stent, reducing dual antiplatelet therapy duration from 12 months to 1 month for specific patients [10][38] - **New Product Approvals**: The domestic knee joint prosthesis received FDA approval, enhancing competitiveness in overseas markets [13][49] Conclusion - **Overall Performance**: MicroPort Medical demonstrated significant improvements in profitability and operational efficiency despite facing market challenges. The company is well-positioned for future growth through strategic partnerships, innovative product offerings, and a focus on international expansion [2][60]

Core Insights - The company reported a revenue of $548 million for 1H25, a year-on-year decrease of 2%, but the net loss attributable to shareholders narrowed to $47 million from $97 million, representing a 52% reduction in loss [1] - Despite revenue pressures, effective cost control and contributions from foreign exchange gains and asset disposals led to better-than-expected profit performance [1] Revenue Trends - Major business segments experienced varying degrees of revenue pressure: - Coronary revenue decreased by 2.1%, with domestic revenue stable and balloon and accessory revenues increasing by 38% and 21% respectively; overseas revenue fell by 10% due to Middle East conflicts and channel adjustments [1] - Orthopedic revenue declined by 3.7%, and cardiac rhythm management revenue decreased by 1.4% [1] - Revenue from large artery and peripheral segments dropped by 9.2%, while neurointervention revenue fell by 6.2% [1] - Structural heart disease revenue increased by 2.7%, surgical robot revenue surged by 77%, and surgical revenue rose by 42.8% [1] - International business revenue grew by 57.3%, reaching $60 million [1] Cost Management and EBITDA - The orthopedic segment's net loss narrowed by 57.9%, with EBITDA increasing by 28.5% [2] - Cardiac rhythm management achieved positive EBITDA, while Heartlink Medical's net loss decreased by 96.2% and minimally invasive robotics' net loss reduced by 58.9% [2] - Overall, total expenses decreased by 14.5% year-on-year, and the operating expense ratio improved by 8.1 percentage points, with R&D expense ratio dropping from 20.6% to 13.2% [2] - The company's overall EBITDA increased to $128 million from $59 million in 1H24 [2] Strategic Initiatives - The company plans to restructure its cardiac rhythm management business, with a potential merger with minimally invasive Heartlink's operations [2] - The company is also looking to sell several properties and other assets, engaging with multiple potential investors to improve its debt and cash flow situation [2] Profit Forecast and Valuation - The profit forecast for 2025/26 remains unchanged at a net profit of -$39 million and $74 million respectively, maintaining an outperform rating [2] - The target price based on DCF model remains at HKD 17, indicating a 40% upside potential from the current price [2]